Mersana Therapeutics : Termination of Material Agreement - Form 8-K
December 21, 2023 at 04:13 pm EST
Share
Item 1.02
Termination of a Material Definitive Agreement
On December 15, 2023, Mersana Therapeutics, Inc. (the "Company") and Merck KGaA mutually agreed to terminate both the Collaboration and Commercial License Agreement dated June 23, 2014 (as amended from time to time, the "2014 Dolaflexin Collaboration Agreement") and the Supply Agreement dated May 30, 2018 (as amended from time to time, the "Dolaflexin Supply Agreement") between the parties. Under the terms of the 2014 Dolaflexin Collaboration Agreement, the Company and Merck KGaA developed research plans to evaluate Merck KGaA's antibodies as antibody-drug conjugates ("ADCs") incorporating the Company's Dolaflexin technology. Under the Dolaflexin Supply Agreement, the Company agreed to provide Merck KGaA with preclinical non-good manufacturing practice ADC drug substance and clinical good manufacturing practice drug substance for use in clinical trials associated with one of the antibodies designated under the 2014 Dolaflexin Collaboration Agreement, as well as to provide Dolaflexin (unconjugated material) for Merck KGaA's use in non-clinical research and development activities and in the manufacture of drug substance.
The terminations of the 2014 Dolaflexin Collaboration Agreement and the Dolaflexin Supply Agreement are effective as of December 15, 2023. The respective rights and obligations of each party under each of the 2014 Dolaflexin Collaboration Agreement and the Dolaflexin Supply Agreement that survive termination of each respective agreement pursuant to the terms and conditions set forth therein shall continue. The termination of the 2014 Dolaflexin Collaboration Agreement does not affect the validity of, amend or modify the Collaboration and Commercial License Agreement, dated December 22, 2022, between the Company and Ares Trading S.A. related to the Company's Immunosynthen platform.
Mersana Therapeutics Inc. published this content on 21 December 2023 and is solely responsible for the information contained therein. Distributed by Public, unedited and unaltered, on 21 December 2023 21:12:34 UTC.
Mersana Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which is focused on the development of antibody-drug conjugates (ADCs), which offer a clinically meaningful benefit for cancer patients with significant unmet needs. It has developed two proprietary and differentiated ADC platforms: Dolasynthen and Immunosynthen. Dolasynthen is its cytotoxic ADC platform that is designed to generate site-specific, homogeneous ADCs. Immunosynthen is its proprietary stimulator of interferon genes (STING)-agonist platform that is designed to generate systemically administered ADCs that locally activate STING signaling in both antigen-expressing tumor cells and in tumor-resident immune cells. The Company's pipeline also includes XMT-1660, a Dolasynthen ADC targeting B7-H4 in a Phase I clinical trial, and XMT-2056, an Immunosynthen ADC targeting a novel epitope of human epidermal growth factor receptor 2 (HER2), in addition to other earlier-stage assets.